Transient Ischemic Attack (TIA) Triage and Evaluation of Stroke Risk
Recruitment status was Recruiting
Transient ischemic attack (TIA) is a transient neurological deficit (speech disturbance, weakness…), caused by temporary occlusion of a brain vessel by a blood clot that leaves no lasting effect.
TIA diagnosis can be challenging and an expert stroke evaluation combined with magnetic resonance imaging (MRI) could improve the diagnosis accuracy.
The risk of a debilitating stroke can be as high as 5% during the first 72 hrs after TIA.
TIA characteristics (duration, type of symptoms, age of the patient), the presence of a significant narrowing of the neck vessels responsible for the patient's symptoms (symptomatic stenosis), and an abnormal MRI are associated with an increased risk of stroke.
An emergent evaluation and treatment of TIA patients by a stroke specialist could reduce the risk of stroke to 2%.
Stanford has implemented an expedited triage pathway for TIA patients combining a clinical evaluation by a stroke neurologist, an acute MRI of the brain and the vessels and a sampling of biomarkers (Lp-PLA2). The investigators are investigating the yield of this unique approach to improve TIA diagnosis, prognosis and secondary stroke prevention. The objective of this prospective cohort study is to determine which factors will help the physician to confirm the diagnosis of TIA and to define the risk of stroke after a TIA.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||TIA Triage Trial and Evaluation of Vascular-Specific Inflammatory BiomarkerLp-PLA2 as a Stratification Tool for TIA Triage and Stroke Risk|
- vascular events [ Time Frame: 90 days ] [ Designated as safety issue: No ]
- Vascular Events [ Time Frame: 7 days ] [ Designated as safety issue: No ]
- Vascular Events [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples Without DNA
2 tiger top or gold top tubes
- Blood specimens should be inverted 10 times before processing.
- Centrifuge and separate within four hours of venipuncture.
- Transfer 1.0 ml into 2 transfer tubes
Freeze at -70 C
|Study Start Date:||September 2010|
|Estimated Study Completion Date:||December 2013|
|Estimated Primary Completion Date:||December 2013 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01423201
|Contact: Stephanie Kemp, BS||(650) firstname.lastname@example.org|
|United States, California|
|Stanford University School of Medicine||Recruiting|
|Stanford, California, United States, 94305|
|Contact: Stephanie Kemp, BS 650-723-4481 email@example.com|
|Principal Investigator: Gregory W Albers|
|Sub-Investigator: Mohamed Teleb|
|Sub-Investigator: Waimei A Tai|
|Sub-Investigator: Anna K. Finley Caulfield|
|Sub-Investigator: Dr. chitra venkat|
|Sub-Investigator: Paul Singh|
|Sub-Investigator: Maarten G Lansberg MD, PhD|
|Sub-Investigator: Neil Schwartz|
|Sub-Investigator: Jean-Marc Olivot|
|United States, Michigan|
|Michigan State University||Recruiting|
|Grand Rapids, Michigan, United States, 49503|
|Contact: Michael Brown, MD 616-391-3050 firstname.lastname@example.org|
|Principal Investigator: Michael Brown|
|Principal Investigator:||Gregory W Albers||Stanford University|